Australia markets open in 29 minutes

Biogen Inc. (BIIB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
213.57+1.64 (+0.77%)
At close: 04:00PM EDT
211.81 -1.76 (-0.82%)
After hours: 07:25PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close211.93
Open210.32
Bid213.99 x 1000
Ask215.90 x 1200
Day's range208.13 - 213.68
52-week range187.16 - 372.12
Volume972,390
Avg. volume1,106,185
Market cap31.278B
Beta (5Y monthly)0.42
PE ratio (TTM)21.86
EPS (TTM)9.77
Earnings date20 July 2022 - 25 July 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est238.74
  • Business Wire

    Biogen and Happify Health Collaborate to Support Multiple Sclerosis Patients on Digital Platform

    CAMBRIDGE, Mass. & NEW YORK, June 22, 2022--Biogen (NASDAQ:BIIB) and Happify Health (www.HappifyHealth.com), the Intelligent Healing Company™, today announced a collaboration to provide a digital solution for patient education and engagement, powered by artificial intelligence (AI), to support people living with multiple sclerosis (MS). Through this collaboration, Biogen and Happify Health will help people with MS manage their care journey, improve their wellbeing, learn about treatment options,

  • Zacks

    Ionis (IONS), AstraZeneca's Amyloidosis Drug Meets Study Goals

    Ionis (IONS), along with partner AstraZeneca, reports positive data from a phase III study, which is evaluating eplontersen in hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).

  • GlobeNewswire

    European Patent Office Grants Patent Related to TECFIDERA® (Dimethyl Fumarate)

    Patent covers approved dosing regimen for TECFIDERA and expires in 2028 CAMBRIDGE, Mass., June 21, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the European Patent Office has granted a patent that expires in February 2028 related to TECFIDERA® (dimethyl fumarate). The patent, EP 2 653 873, is directed to treating multiple sclerosis using dimethyl fumarate dosed at 480mg per day, which is the European Medicines Agency (EMA) recommended maintenance dose for TECFIDERA. P